RecruitingColon AdenocarcinomaColorectal AdenocarcinomaRectal Adenocarcinoma

Family Communications After Genetic Testing

Eligible age

18+ yrs

Accepts

All genders

Locations

28 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.

Sponsor: Alliance for Clinical Trials in Oncology

You may qualify if…

✓ STEP 1 PROBANDS: Age \>= 18 years
✓ STEP 1 PROBANDS: Patients with a newly diagnosed (within 3 months of registration), primary colorectal adenocarcinoma, stage I to IV
✓ Histologically proven stage I to IV colon or rectal adenocarcinoma (any T or N, M+). Tumors deemed to originate in the colon can extend into/involve the small bowel (e.g., those at the ileocecal valve). Tumors will be regarded as originating in the colon if the entire tumor is in the colon. In the case of rectal involvement, the cancer will be considered a rectal primary
✓ Patients with more than one primary colon adenocarcinoma are eligible
✓ STEP 1 PROBANDS: No patients with stage 0 or in-situ colorectal cancer
✓ STEP 1 PROBANDS: Patients who have had prior malignancies are eligible, including non-invasive cancers
✓ STEP 1 PROBANDS: Patients with synchronous second malignancies are eligible
✓ STEP 1 PROBANDS: Have not received germline testing in the 2 years prior to enrollment or known hereditary colon cancer syndromes